Related Experiment Videos

Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells

A Budillon1, P Tagliaferri, M Caraglia

  • 1Cattedra di Oncologia Medica, II Facoltà di Medicina, Università Napoli, Italy.

Cancer Research
|February 15, 1991
PubMed

Insights

Recombinant alpha-interferon (IFN-alpha) increases epidermal growth factor receptor (EGF-R) synthesis and binding capacity in human cancer cells. This finding suggests IFN-alpha as a potential therapeutic strategy for cancers driven by EGF-R.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Unregulated epidermal growth factor receptor (EGF-R) expression is common in cancer.
  • Modulating EGF-R activity with physiological agents holds clinical potential for cancer therapy.

Purpose of the Study:

  • To investigate the effects of recombinant alpha-interferon (IFN-alpha) on EGF-R binding, cell surface availability, and synthesis in human epidermoid cancer cell lines (A431 and KB).

Main Methods:

  • Treatment of A431 and KB cells with IFN-alpha.
  • Assessment of EGF-R binding using [125I]EGF.
  • Analysis of receptor synthesis via immunoprecipitation of [35S]methionine-labeled cell extracts.
  • Confirmation of cell surface receptor levels using electron microscopy.

Main Results:

  • IFN-alpha induced growth inhibition and enhanced HLA expression in both cell lines.
  • A dose-dependent upregulation of EGF-R binding capacity was observed after IFN-alpha treatment.
  • IFN-alpha increased the number of low-affinity EGF-R, primarily by enhancing receptor protein synthesis.
  • Electron microscopy confirmed increased EGF-R on the cell surface without significant morphological changes.

Conclusions:

  • IFN-alpha consistently increases both the binding capacity and synthesis of EGF-R in human epidermoid cancer cells.
  • The mechanism suggests a potential role for IFN-alpha in novel anticancer therapies targeting EGF-R.

Related Concept Videos